A PDGFRalpha in combination with doxorubicin for the treatment of advanced soft tissue sarcoma who are not candidates for radiotherapy or surgery.
A human IgG1 monoclonal antibody that binds to PDGFRalpha and blocks the PDGF-AA, PDGF-BB and PDGF-CC ligands from binding to the receptor.
The combination of this drug with doxorubicin reduced the risk of death by 48% compared to doxorubicin alone.
Median survival time for the combination of drugs was 26.5 months compared to 14.7 months with doxorubicin alone.
Trade name Lartruvo.
An intravenous agent that is a platelet-derived growth factor receptor alpha blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma with the histologic subtype for which an anthracycline containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
Given at 15 mg per kilogram as an intravenous infusion over 60 minutes on days one and eight of each 21 day cycle until disease progression or unacceptable toxicity.
And it is administered for the first eight cycles with doxorubicin.
Is premedicated with diphenhydramine and dexamethasone intravenously prior to treatment on day one of cycle one.
The most common adverse reactions for this agent plus doxorubicin include: nausea, fatigue, musculoskeletal pain, mucositus, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy, and headache.
The most common laboratory abnormalities are: lymphopenia, neutropenia, thrombocytopenia, hyperglycemia, elevated PTT, hypokalemia, and hypophosphatemia.
Study shows a 26.5 median overall survival for this agent plus doxorubicin versus 14.7 months median overall survival for doxorubicin alone.
In the above study Lartruvo plus doxorubicin had an 8.2 months median progression free survival versus 4.4 months for the median progression free survival for doxorubicin alone.
In the above study Lartruvo plus doxorubicin increased objective response rate by 18.2% versus doxorubicin alone at 7.5%.
Subsequent phase 3 studies of this drug in sarcoma showed no improvement in overall survival.